Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Development of a lead cyclic-PDZ-Enhancer drug for Anxiety and Depression

    SBC: Aingeal, LLC            Topic: 101

    Major depressive disorder is a debilitating mood disorder that affectsof US adults in their lifetimecosting the U Seconomy more than $billion a yearDrugs that increase monoaminergic signaling are the mainstay of depression therapybut have a delayed onset of action and are only effective in aboutof affected patientsAberrant brain derived neurotrophic factorBDNFsignaling has been proposed to underli ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Novel High-Resolution Scintillation X-ray Detectors for Digital Dentistry

    SBC: NGS Detectors LLC            Topic: NIDCR

    Project SummaryNovel High Resolution Scintillation X ray Detectors for Digital Dentistry The transition from traditional film to digital X ray detectors has resulted in significant improvements across many areas for dental X ray imaging ranging from decreased wait timesimproved logistics and even lower radiation dose ratesOne significant drawback remains with digital X ray imaging howeverwhich is ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government